In particular, a combination of pemafibrate and drugs that enhance the excretion or inhibit the absorption of carbohydrates and lipids (e.g., an SGLT2 inhibitor, α-glucosidase inhibitor, or pancreatic intestinal lipase inhibitor) has the potential to improve TG accumulation and inflammation in NASH livers. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.